# Green Cross Corporation clinical trials: 63 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 63 trials with Green Cross Corporation as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Green Cross Corporation: 63 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/green-cross-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 63
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 63, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 16, 2022 | NCT05422508 | Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of... | Green Cross Corporation | Phase 2 | Recruiting | Varicella | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05422508) |
| September 18, 2020 | NCT04555148 | COVIDIG (COVID-19 Hyper-ImmunoGlobulin) | Green Cross Corporation | Phase 2 | Completed | Covid19 | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04555148) |
| January 23, 2020 | NCT04238975 | A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults | Green Cross Corporation | Phase 2 | Unknown | Tetanus, Diphtheria, Whooping Cough | 213 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04238975) |
| November 25, 2019 | NCT04175522 | Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: | Green Cross Corporation | Phase 2 | Completed | Autoimmune Encephalitis | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04175522) |
| July 1, 2019 | NCT04003844 | Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease | Green Cross Corporation | Phase 4 | Completed | Kawasaki Disease | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04003844) |
| May 13, 2019 | NCT03947138 | A Study of GC3107(BCG Vaccine) in Healthy Infants | Green Cross Corporation | Phase 3 | Completed | BCG Vaccination Reaction, Tuberculosis | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03947138) |
| April 19, 2019 | NCT03920540 | A Study of GC1111 in Hunter Syndrom Patients | Green Cross Corporation | Phase 3 | Completed | Hunter Syndrome | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03920540) |
| February 27, 2019 | NCT03855696 | A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients | Green Cross Corporation | Phase 1 | Completed | Hemophilia | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03855696) |
| January 14, 2019 | NCT03801798 | A Study of GC1102(Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients | Green Cross Corporation | Phase 2 | Unknown | Hepatitis B | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03801798) |
| September 5, 2018 | NCT03657719 | A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects | Green Cross Corporation | Phase 2 | Completed | Influenza, Human | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03657719) |
| May 8, 2018 | NCT03519113 | HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102 | Green Cross Corporation | Phase 2/3 | Unknown | Hepatitis B Infection | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03519113) |
| April 10, 2018 | NCT03492710 | Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency | Green Cross Corporation | Phase 3 | Withdrawn | Primary Immune Deficiency Disorder | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03492710) |
| March 6, 2018 | NCT03454620 | A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy | Green Cross Corporation | Phase 1/2 | Completed | Metastatic Colorectal Cancer, Solid Tumor | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03454620) |
| December 18, 2017 | NCT03375502 | A Study of MG1111 in Healthy Children | Green Cross Corporation | Phase 2/3 | Completed | Healthy Children | 814 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03375502) |
| December 6, 2017 | NCT03363178 | Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults | Green Cross Corporation | Phase 1 | Unknown | Tuberculosis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03363178) |
| November 29, 2017 | NCT03357263 | A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults | Green Cross Corporation | Phase 1 | Completed | Influenza, Human | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03357263) |
| September 18, 2017 | NCT03285997 | A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age | Green Cross Corporation | Phase 3 | Unknown | Influenza Vaccine | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03285997) |
| September 28, 2016 | NCT02917304 | A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older | Green Cross Corporation | Phase 3 | Completed | Influenza, Human | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02917304) |
| September 27, 2016 | NCT02915809 | A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults | Green Cross Corporation | Phase 3 | Unknown | Influenza, Human | 414 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02915809) |
| June 27, 2016 | NCT02813486 | Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine | Green Cross Corporation | Phase 1/2 | Unknown | Tetanus, Diphtheria, Whooping Cough | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02813486) |
| May 26, 2016 | NCT02783482 | Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency | Green Cross Corporation | Phase 3 | Completed | Immunologic Deficiency Syndromes | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02783482) |
| January 26, 2016 | NCT02663024 | Study of Idursulfase-beta (GC1111) in Hunter Syndrome | Green Cross Corporation | Phase 2 | Unknown | Mucopolysaccharidosis II | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02663024) |
| January 18, 2016 | NCT02658409 | A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study | Green Cross Corporation | Phase 3 | Unknown | Influenza | 1,630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02658409) |
| October 6, 2015 | NCT02569372 | A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients | Green Cross Corporation | Phase 1 | Completed | Chronic Hepatitis B | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02569372) |
| September 18, 2015 | NCT02553837 | Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult | Green Cross Corporation | Phase 3 | Unknown | Healthy | 317 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02553837) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 1/2 | 6 |
| Phase 2 | 10 |
| Phase 2/3 | 4 |
| Phase 3 | 25 |
| Phase 4 | 4 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 43 |
| Unknown | 16 |
| Terminated | 2 |
| Recruiting | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Influenza, Human | 13 |
| Mucopolysaccharidosis II | 5 |
| Hemophilia A | 4 |
| Hepatitis B | 4 |
| Osteoarthritis | 3 |
| Colorectal Neoplasms | 2 |
| Tuberculosis | 2 |
| Sudden Infant Death | 2 |
| Influenza in Birds | 2 |
| Chickenpox | 2 |
| Immunologic Deficiency Syndromes | 2 |
| Primary Immunodeficiency Diseases | 2 |
| Tetanus | 2 |
| Diphtheria | 2 |
| Whooping Cough | 2 |
| Mucocutaneous Lymph Node Syndrome | 2 |
| Hepatitis B, Chronic | 2 |
| Bacterial Infections | 2 |
| Autoimmune Diseases of the Nervous System | 1 |
| Purpura, Thrombocytopenic, Idiopathic | 1 |
| Fabry Disease | 1 |
| Thyroid Diseases | 1 |
| Anthrax | 1 |
| Sepsis | 1 |
| Shock, Septic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Wine wholesalers in the United States](https://specstream.ai/data/businesses/wine-wholesalers/united-states)
- [Metal fabricators in the United States](https://specstream.ai/data/businesses/metal-fabricators/united-states)
- [Commercial printers in the United States](https://specstream.ai/data/businesses/commercial-printers/united-states)
- [South African restaurants in the United States](https://specstream.ai/data/businesses/south-african-restaurants/united-states)
- [Home security companies in the United States](https://specstream.ai/data/businesses/home-security-companies/united-states)
- [B2B marketing consultants in the United States](https://specstream.ai/data/businesses/b2b-marketing-consultants/united-states)
